JB
Therapeutic Areas
BioMarin Pharmaceutical Pipeline
| Drug | Indication | Phase |
|---|---|---|
| VOXZOGO (vosoritide) | Achondroplasia | Approved/Marketed |
| ROCTAVIAN (valoctocogene roxaparvovec) | Severe Hemophilia A | Approved/Marketed |
| PALYNZIQ (pegvaliase-pqpz) | Phenylketonuria (PKU) | Approved/Marketed |
| BMN 331 (giroctocogene fitelparvovec) | Severe Hemophilia B | Phase 1/2 |
| BMN 349 | Genetic Cardiomyopathy | Preclinical |
| BMN 355 | Undisclosed Genetic CNS Disorder | Preclinical |
Leadership Team at BioMarin Pharmaceutical
AH
Alexander Hardy
President and Chief Executive Officer
BR
Brian R. Mueller
Executive Vice President, Chief Financial Officer
GF
Greg Friberg
Executive Vice President, Chief Research & Development Officer
CH
Cristin Hubbard
Executive Vice President, Chief Commercial Officer
CG
C. Greg Guyer
Executive Vice President, Chief Technical Officer
JS
James Sabry
Executive Vice President, Chief Business Officer
AW
Amy Wireman
Executive Vice President, Chief People Officer
GE
G. Eric Davis
Executive Vice President, Chief Legal Officer
AD
Arpit Davé
Executive Vice President, Chief Digital and Information Officer
MK
Marni Kottle
Executive Vice President, Chief Corporate Affairs & Patient Advocacy Officer